<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="571">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01559220</url>
  </required_header>
  <id_info>
    <org_study_id>2011H0362</org_study_id>
    <nct_id>NCT01559220</nct_id>
  </id_info>
  <brief_title>Deep Brain Stimulation for the Treatment of Alzheimer's Disease</brief_title>
  <official_title>Deep Brain Stimulation (DBS) for Treatment of the Cognitive, Behavioral, and Functional Disability of Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ali Rezai, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to investigate the safety and efficacy of deep brain&#xD;
      stimulation (DBS)as a treatment option for patients with cognitive, behavioral, and&#xD;
      functional disability of Alzheimer's disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open label pilot study&#xD;
&#xD;
        -  Expected direct benefit on the modulation of neuronal networks.&#xD;
&#xD;
        -  Expected indirect benefit via potential enhancements of memory, executive functions,&#xD;
           cognition behavioral control, and functional abilities.&#xD;
&#xD;
      Up to 10 subjects will be implanted with bilateral DBS systems, participants are expected to&#xD;
      be on study for about 23 months.&#xD;
&#xD;
        -  Develop a multidisciplinary clinical research protocol to evaluate the efficacy of&#xD;
           ventral striatum, nucleus accumbens, and internal capsule for the amelioration of&#xD;
           disability caused by Alzheimer's Disease.&#xD;
&#xD;
        -  Enroll up to 10 patients into an open label study to evaluate the safety and efficacy of&#xD;
           DBS for Alzheimer's Disease patients with mild to moderate disability.&#xD;
&#xD;
        -  Determine an initial DBS titration and stimulation settings protocol for use in&#xD;
           subsequent controlled trials.&#xD;
&#xD;
        -  Evaluate the outcomes of this study based on clinical, laboratory, biomarker, imaging,&#xD;
           cognitive, behavioral, and functional assessments.&#xD;
&#xD;
        -  Determine what domains of cognitive, behavioral and functioning impairment show the&#xD;
           greatest response to DBS.&#xD;
&#xD;
        -  Examine the potential benefit of stimulation combined with behavioral and rehabilitation&#xD;
           interventions in comparison to stimulation alone.&#xD;
&#xD;
        -  Evaluate the influence of DBS on physiological and functional changes in cortical and&#xD;
           subcortical networks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Dementia Rating Scale</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Open Label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DBS Implant and stimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Deep Brain Stimulation</intervention_name>
    <description>Implanted device</description>
    <arm_group_label>Open Label</arm_group_label>
    <other_name>Deep Brain Stimulation Device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of probable AD according to the National Institute of Neurological and&#xD;
             Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders&#xD;
             Association (NINCDS-ADRDA) criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has significant neurological disease, other than Alzheimer's disease, e.g., multiple&#xD;
             sclerosis, Parkinson's disease and ischemic stroke, or severe brain atrophy or the&#xD;
             presence of subdural hygromas or subdural hematomas.&#xD;
&#xD;
          -  Evidence of substance abuse (alcohol or other drug) abuse or dependence during the&#xD;
             previous 12 months (DSM-IV Criteria).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ali Rezai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wexner Medical Center at the Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>March 19, 2012</study_first_submitted>
  <study_first_submitted_qc>March 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2012</study_first_posted>
  <last_update_submitted>March 28, 2017</last_update_submitted>
  <last_update_submitted_qc>March 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Ali Rezai, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

